Vertex Pharmaceuticals (VRTX)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 2 |
| Ownership rank: | 481 |
| % of all portfolios: | 0.032% |
| Hold Price * : | $446.52 |
| History | Portfolio Manager | Activity | Share change | % change to portfolio ▲ | |
| Q1 2026 | |||||
| ≡ | Torray Funds | Reduce 0.52% | 80 | 0.01 | |
| Q4 2025 | |||||
| ≡ | Torray Funds | Reduce 4.85% | 789 | 0.06 | |
| Q3 2025 | |||||
| ≡ | Torray Funds | Reduce 3.70% | 624 | 0.03 | |
| Q2 2025 | |||||
| ≡ | Tweedy Browne | Reduce 2.77% | 1,063 | 0.04 | |
| Q1 2025 | |||||
| ≡ | Torray Funds | Reduce 1.79% | 287 | 0.02 | |
| ≡ | Tweedy Browne | Reduce 5.70% | 2,315 | 0.10 | |
| Q4 2024 | |||||
| ≡ | Tweedy Browne | Reduce 24.20% | 12,969 | 0.35 | |
| ≡ | John Armitage - Egerton Capital | Sell 100.00% | 124,045 | 0.58 | |
| Q3 2024 | |||||
| ≡ | Tweedy Browne | Reduce 1.37% | 746 | 0.02 | |
| Q2 2024 | |||||
| ≡ | Tweedy Browne | Reduce 18.52% | 12,353 | 0.27 | |
| Q1 2024 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 812 | 0.01 | |
| ≡ | Torray Funds | Reduce 1.20% | 169 | 0.01 | |
| Q4 2023 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 44.27% | 645 | 0.01 | |
| Q4 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 18,052 | 0.04 | |
| Q2 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 6,254 | 0.01 | |
| Q2 2020 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 460 | 0.00 | |
| Q2 2015 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 524,867 | 1.00 | |
| Q2 2009 | |||||
| ≡ | Bill & Melinda Gates Foundation Trust | Sell 100.00% | 95,000 | 0.03 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.